Relmada Therapeutics
RLMD
$0.53
Share price
10.78%
Change (1 day)
-93.56%
Change (1 year)
Categories
Relmada Therapeutics (RLMD) - P/B ratio
P/B ratio as of April 2025 : 0.2098
According to Relmada Therapeutics's latest financial reports the company has a price-to-book ratio of 0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Relmada Therapeutics - P/B ratio (from 2014 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | 0.2427 | -83.38% |
| 2023-12-31 | 1.46 | 95.17% |
| 2022-12-31 | 0.7480 | -75.07% |
| 2021-12-31 | 3.00 | -39.51% |
| 2020-12-31 | 4.96 | 1.78% |
| 2019-12-31 | 4.87 | -79.57% |
| 2018-12-31 | 23.9 | 82.88% |
| 2017-12-31 | 13.0 | 364.91% |
| 2016-12-31 | 2.81 | 10.05% |
| 2015-12-31 | 2.55 | -92.96% |
| 2014-12-31 | 36.2 | |
| 2013-12-31 | N/A | |
| 2012-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | P/B ratio differencediff. | Country |
|---|---|---|---|
 | 0.9078 | 332.73% | 🇮🇱 Israel |
 | -36.5 | -17,491.85% | 🇺🇸 USA |